Age and Location in Severity of COVID‐19 Pathology: Do Lactoferrin and Pneumococcal Vaccination Explain Low Infant Mortality and Regional Differences?

BioEssays - Tập 42 Số 11 - 2020
Robert Root‐Bernstein1,2
1Department of Physiology, Michigan State University, East Lansing, MI 48824, USA
2*Email: [email protected]

Tóm tắt

AbstractTwo conundrums puzzle COVID‐19 investigators: 1) morbidity and mortality is rare among infants and young children and 2) rates of morbidity and mortality exhibit large variances across nations, locales, and even within cities. It is found that the higher the rate of pneumococcal vaccination in a nation (or city) the lower the COVID‐19 morbidity and mortality. Vaccination rates with Bacillus Calmette–Guerin, poliovirus, and other vaccines do not correlate with COVID‐19 risks, nor do COVID‐19 case or death rates correlate with number of people in the population with diabetes, obesity, or adults over 65. Infant protection may be due to maternal antibodies and antiviral proteins in milk such as lactoferrin that are known to protect against coronavirus infections. Subsequent protection might then be conferred (and correlate with) rates of Haemophilus influenzae type B (Hib) (universal in infants) and pneumococcal vaccination, the latter varying widely by geography among infants, at‐risk adults, and the elderly. Also see the video abstract here https://youtu.be/GODBYRbPL00.

Từ khóa


Tài liệu tham khảo

10.3855/jidc.12600

10.1183/13993003.00749-2020

10.15585/mmwr.mm6914e4

NYC Health Daily Data Summary https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-19-daily-data-summary-deaths-05132020-1.pdf(accessed: May 2020).

C.Harris COVID‐19 Coronavirus Breakdown of Deaths and Infections Worldwide.EuroNews https://www.euronews.com/2020/05/14/covid-19-coronavirus-breakdown-of-deaths-and-infections-worldwide(accessed: May 2020).

China CCDC The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID‐19) ‐China CCDC http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51(accessed: February 2020).

10.1016/j.cmi.2018.02.004

10.4172/2324-8955.1000104

10.1086/591708

10.1016/S1473-3099(06)70466-2

Sun H., 2012, Milk Protein

10.1016/j.vaccine.2017.09.002

10.1016/j.jiac.2014.08.003

10.1186/s13568-019-0900-8

10.1186/1471-2172-6-2

10.1371/journal.pone.0023710

Serrano G., 2020, Int. J. Res. Health Sci., 8, 8

R.Chang W.‐Z.Sun T. B.Ng Lactoferrin as Potential Preventative and Treatment for COVID‐19. ResearchGate preprint 2020 https://doi.org/10.22541/au.158630054.41052564

10.1586/erv.11.99

10.1128/CVI.05675-11

10.1155/2006/862797

Cucchiari D., 2020, Med. Clin.

Clancy C. J., 2020, Clin. Infect. Dis.

Rawson T. M., 2020, Clin. Infect. Dis.

10.1002/ppul.24718

10.1016/j.jinf.2020.03.019

10.1111/all.14238

Liu G. S., 2019, Biomed. Environ. Sci., 32, 438

10.1007/s10096-019-03583-2

10.1007/s10096-019-03614-y

George R. C., 1983, Br. J. Exp. Pathol., 64, 655

10.1093/infdis/141.2.172

10.1007/s10096-017-2990-z

Lopalco P. L., 2006, Euro. Surveill., 11, pii = 3092

Nuorti J. P., 2010, MMWR Recomm. Rep., 59, 1

D.Ward Sampling Bias Case Fatality Rates and COVID‐19 Testing: A Further Analysis. ResearchGate preprint 2020 https://doi.org/10.13140/RG.2.2.29057.89448

A.Miller M. J.Reandelar K.Fasciglione V.Roumenova Y.Li G. H.Otazu medRxiv preprint 2020 https://doi.org/10.1101/2020.03.24.20042937

10.15252/emmm.202012661

10.3389/fimmu.2020.00970

K.Chumakov R.Gallo Could an Old Vaccine Be a Godsend for New Coronavirus? Using the Oral Polio Vaccine Could Prevent or Reduce the Spread of COVID‐19 to Immunized Individuals. USA Today https://www.usatoday.com/story/opinion/2020/04/21/oral-polio-vaccine-has-potential-treat-coronavirus-column/5162859002/(accessed: April 2020).

10.1016/S2468-1253(17)30154-1

10.1016/j.arbres.2013.09.016

10.1016/j.vaccine.2018.05.026

10.1016/S1473-3099(18)30346-3

10.1016/j.clinthera.2014.03.001

J.Mereckiene Seasonal Influenza Vaccination in Europe: Vaccination Recommendations and Coverage Rates in the EU Member States for Eight Influenza Seasons: 2007–2008 to 2014–2015; Technical Report; European Centre for Disease Prevention and Control: Solna Sweden 2017.https://ecdc.europa.eu/sites/portal/files/documents/influenza-vaccination-2007%E2%80%932008-to-2014%E2%80%932015.pdf

Blank P. R., 2018, Hum. Vaccines Immunother., 14, 2706

10.1371/journal.pone.0210081

10.1186/s12879-019-3735-7

Hull B., 2019, Commun. Dis. Intell. (2018), 43

10.1186/s12879-016-1820-8

Kaplan A., 2019, Can. Fam. Physician, 65, 625, 10.46747/cfp.6509625

10.17269/s41997-018-0018-9

10.1186/s13054-020-2769-y

Theidel U., 2013, Deutsches Ärzteblatt Int., 110, 743

10.1016/j.vaccine.2016.03.052

10.3947/ic.2018.50.4.328

Chan D., 2010, Pub. Health Epidem. Bull., 19, 53

Corcoran M., 2019, Irish Med. J., 112, 894

10.1016/j.vaccine.2012.10.077

10.1080/21645515.2018.1475812

10.1371/journal.pone.0166637

10.1016/j.vaccine.2013.12.044

10.1016/j.jiac.2019.12.011

10.4103/jgid.jgid_167_17

10.1186/s12879-019-4186-x

Kumar M., 2014, Value Health, 17, PA804

10.1016/j.idh.2019.07.002

10.21149/spm.v55s2.5128

10.1016/j.vaccine.2019.08.025

10.1371/journal.pone.0209428

10.3349/ymj.2013.54.2.469

10.3947/ic.2015.47.1.41

10.1016/j.vaccine.2016.01.043

Kim S. H., 2016, Biomed Res. Int., 2016, 6950482

10.3343/alm.2019.39.6.537

Büla C. J., 1996, Schweiz. Med. Wochenschr., 126, 2082

10.1007/s00520-015-3037-6

Centers for Disease Control and Prevention 2008 through 2018 Adult Vaccination Coverage Trend Report https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/data-reports/general-population/trend/index.html(accessed: April 2020).

Centers for Disease Control and Prevention FluVaxView https://www.cdc.gov/flu/fluvaxview/coverage-1819estimates.htm(accessed: March 2020).

10.1016/j.amepre.2019.10.022

10.1186/s12879-018-3326-z

10.1016/j.vaccine.2017.05.075

10.15585/mmwr.ss6501a1

10.1016/S2214-109X(18)30455-8

10.1111/irv.12374

10.1590/S0034-89102005000100017

10.1080/21645515.2018.1514225

10.1017/S0950268819000037

10.17843/rpmesp.2017.344.2884

10.1016/j.vaccine.2017.09.005

10.1016/j.vaccine.2018.09.032

MDHHS Michigan Department of Health and Human Services County Immunization Report Card https://www.michigan.gov/mdhhs/0 5885 7-339-73971_4911_4914_68361-321114- 00.html(accessed: April 2020).

Louisiana Department of Health Health Data.https://healthdata.dhh.la.gov/and Coronavirus datahttp://ldh.la.gov/Coronavirus/(accessed: April 2020).

Worldometer Coronavirus https://www.worldometers.info/coronavirus/country/us/(accessed: April 2020).

Centers for Disease Control and Prevention Childhood Pneumococcal Conjugate Vaccine (PCV) Coverage Report https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/data-reports/pcv/reports/2017.html(accessed: April 2020).

Centers for Disease Control and Prevention (CDC), 2006, Morb. Mortal. Wkly. Rep., 55, 1065

10.1542/peds.108.4.e60

10.1111/j.1532-5415.2010.03181.x

10.15585/mmwr.mm6643a3

10.1016/j.amepre.2015.03.005

10.2105/AJPH.2017.304257

10.1080/21645515.2018.1564434

10.1586/14760584.2015.963058

Westerink M. A., 2012, Aging Dis., 3, 51

10.1128/CVI.00721-15

10.1007/s00277-019-03615-z

10.1086/375782

M.Charley R.Reid Impact of PCV13 on Carriage. Johns Hopkins Center for American Indian Health. Unpublished lecture October 18 2017 https://www.nnhrrb.navajo-nsn.gov/pdf/2017/2017conf_day1/Impact%20of%20Routine%20PCV13%20on%20Carriage.pdf(accessed: May 2020).

10.1002/ajh.25785

10.1016/j.vaccine.2009.01.135

10.4161/hv.22550

10.1023/A:1007398606807

10.1093/eurpub/ckx150

10.1002/1096-9071(200011)62:3<383::AID-JMV11>3.0.CO;2-#

10.1073/pnas.96.5.2279

10.1016/j.chom.2014.07.003

10.1126/science.aab1253

R.Root‐Bernstein Cross‐Reactivity Between SARS‐CoV‐2 Proteins and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS‐CoV‐2 Disease and Death. Preprints 2020 https://doi.org/10.20944/preprints202007.0141.v1

10.1084/jem.54.3.349

10.1084/jem.54.3.361

10.1084/jem.54.3.373

10.1016/S0140-6736(86)92073-8

10.1080/08916930802208540

10.1016/j.autrev.2006.09.003

10.3390/ijms21134645

10.1056/NEJMc2009191

10.1007/s13365-020-00840-5

10.1016/S0140-6736(20)31129-6

10.1007/BF00841840

10.1128/IAI.00789-06

10.1128/CMR.00111-17

10.1016/j.clinthera.2008.02.003

10.26719/emhj.19.039

10.1016/j.jval.2018.07.504

Statens Serum Institute Selected Risk Groups are Offered Free Pneumococcal Vaccination https://www.sst.dk/da/Nyheder/2020/Udvalgte-risikogrupper-faar-tilbud-om-gratis-vaccination-mod-pneumokokker(accessed: April 2020).

National Institute for Communicable Diseases (South Africa) Pneumococcal Conjugate Vaccine Use in the Light of the COVID‐19 Pandemic https://www.nicd.ac.za/diseases-a-z-index/covid-19/advice-for-the-public/pneumococcal-conjugate-vaccine-use-in-the-light-of-the-covid-19-pandemic/(accessed: July 2020).

Y. H.Choi E.Miller medRxivpreprint 2020 https://doi.org/10.1101/2020.06.01.20119057

10.1001/jama.294.16.2043

Wiese A. D., 2019, Vaccines, 18, 327

10.1016/j.vaccine.2010.04.035

Thông tin
Thông tin xuất bản

BioEssays

Tập 42 Số 11

Thông tin tác giả